People · Operator
Named in public records as an officer, director or promoter · active 2009–2009 · Biotechnology
| Company | Role | Sector | Stage | Raised · real | Value · est | Tied |
|---|---|---|---|---|---|---|
| Mabvax Therapeutics Inc | — | Biotechnology | Series A | $15.6M | $109.9M | 2009 |
Douglas D. Lind at the center, the companies they're named on, and every other operator named alongside them — an interlock map of shared founding teams, boards and funds. Name-matched, so treat as a research lead.
People named alongside Douglas D. Lind on the same companies — an interlock signal (shared founding team, board, or fund). Name-matched, so verify before acting.
| Operator | Shared | Their companies |
|---|---|---|
| Kenneth M. Cohen | 1 | 3 |
| Paul M. Maier | 1 | 3 |
| Jeffrey V. Ravetch | 1 | 2 |
| J. David Hansen | 1 | 2 |
| Jim J. Antonopoulos | 1 | 2 |
| Philip Livingston | 1 | 2 |
| Gregory P. Hanson | 1 | 2 |
| Philip O. Livingston | 1 | 2 |
| Nick Stephens | 1 | 1 |
| James David Antonopoulos | 1 | 1 |
People are matched by normalized name across records; a common name may merge distinct individuals. Treat as a research lead, the same way modeled valuations are directional, not quoted.